French Biotech and Pharma Companies 17-10-2013!17!20

FRENCH BIOTECH
AND PHARMA
COMPANIES
BIO EUROPE 2O13

CONVENTION
4-6 NOVEMBER - VIENNA
contents
INSTITUTIONAL PARTNERS
ATLANPOLE BIOTHERAPIES. .............................................................................................................................................................................6
MEDICEN PARIS REGION........................................................................................................................................................................................6
global care.........................................................................................................................................................................................................................7
GENOPOLE..................................................................................................................................................................................................................................8
COMPANIES
AFFILOGIC................................................................................................................................................................................................................................ 10
ALIZE PHARMA. ................................................................................................................................................................................................................ 10
ALSACE INTERNATIONAL. ................................................................................................................................................................................. 11
AMYLGEN.................................................................................................................................................................................................................................. 11
Ariana Pharmaceuticals........................................................................................................................................................................ 12
ATLANPOLE BIOTHERAPIES. ......................................................................................................................................................................... 12
ATLANTIC BONE SCREEN.................................................................................................................................................................................. 13
BIOALTERNATIVES....................................................................................................................................................................................................... 13
BIOMEDICAL TISSUES............................................................................................................................................................................................. 14
CARLINA Technologies................................................................................................................................................................................. 14
Cellvax sas. ...................................................................................................................................................................................................................... 15
Ciloa sas................................................................................................................................................................................................................................ 15
CiToxLAB sas.................................................................................................................................................................................................................... 16
Cytune Pharma.......................................................................................................................................................................................................... 16
DRUGABILIS.......................................................................................................................................................................................................................... 17
EUKARYS................................................................................................................................................................................................................................... 17
GENBIOTECH ...................................................................................................................................................................................................................... 18
GENOPOLE.............................................................................................................................................................................................................................. 18
icm..................................................................................................................................................................................................................................................... 19
ICTA................................................................................................................................................................................................................................................... 19
In-Cell-Art....................................................................................................................................................................................................................... 20
contents
Iris Pharma....................................................................................................................................................................................................................... 20
Iris Pharma....................................................................................................................................................................................................................... 21
l2d services sarl. ................................................................................................................................................................................................ 21
MedinCell........................................................................................................................................................................................................................... 22
Metabolys sas. ............................................................................................................................................................................................................ 22
METABRAIN RESEARCH....................................................................................................................................................................................... 23
MYELOMAX.............................................................................................................................................................................................................................. 23
OTR3................................................................................................................................................................................................................................................. 24
OXELTIS........................................................................................................................................................................................................................................ 24
PELVIPHARM sas.......................................................................................................................................................................................................... 25
PORSOLT sas...................................................................................................................................................................................................................... 25
POXEL sa. ................................................................................................................................................................................................................................. 26
Prestwick Chemical sas.......................................................................................................................................................................... 26
PUP PHARMA sas........................................................................................................................................................................................................ 27
PXTherapeutics...................................................................................................................................................................................................... 27
QUINTEN.................................................................................................................................................................................................................................... 28
SKULDTECH.......................................................................................................................................................................................................................... 28
SYNCROSOME..................................................................................................................................................................................................................... 29
TEXCELL..................................................................................................................................................................................................................................... 29
Trophos................................................................................................................................................................................................................................... 30
VFP Therapies............................................................................................................................................................................................................... 30
notes
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
INSTITUTIONAL PARTNERS
ATLANPOLE BIOTHERAPIES
CONTACT:
Gregory BAUER
bauer@atlanpole.fr
95, route de Gachet

Chteau de la Chantrerie
44307 NANTES Cedex 3
Tel: +33 (0)2 40 25 27 20
www.atlanpolebiotherapies.fr
ATLANPOLE BIOTHERAPIES gives you access to extended skills, from biodiagnostics to biomedicine
in 3 major areas: immunobiotherapies, radiopharmaceuticals and regenerative medicine. For
pharmaceutical companies looking for high level partners devoted to healthcare and biotech,
ATLANPOLE BIOTHERAPIES is a cluster that draws together a community of innovative companies,
fundamental & clinical research organizations and higher education institutions, all located in
Western France.
Date of creation: 2005
MEDICEN PARIS REGION

SECTOR: R&D Services/Biotechnologies
CONTACT:
Francois CHEVILLARD
medicen@medicen.org
3-5, impasse Reille

75014 PARIS
Tel: +33 (0)1 79 68 10 86
www.medicen.org
MEDICEN PARIS REGION, excellence at the heart of Europe MEDICEN PARIS REGION is your
best gateway to access European biotechnologies and markets. Our mission is to maintain and
reinforce the Paris Region as Europes leading industrial center for diagnostic innovation and health
technologies.
3 R&D themes: 1) Translational medicine; 2) Biological tools for industrial use, biotherapeutic
products; 3) Digital biology.
3 consolidated disease areas and 2 arising areas: 1) Cancer 2) Neurology 3) Infectiology 4)
Cardiometabolism 5) Rare diseases.
RUEP
CEA
ANR-11-CNRT-04
LC
M
OA
AL
BP
AN
R-11-CNRT-02
GLOBAL CARE
TITRE
Lieu
Date
The Global Partnership Research Initiative
CONTACT
xxx
xxx@xxx
Tl.
B U L L E T I N
PROGRAMME
of the Carnot Human Health Institutes
D I N S C R I P T I O N
CONTACT:
x
x
www.x
GLOBAL CARE is an outstanding consortium of 5 French expertise centers (honored by the Carnot
institute label) research that covers 4 therapeutic fields of major interest in human health: oncology,
ophthalmology, infectious diseases and neurology.
Supported by our past experience in partnership research and in property management and by the
fame of its members, GLOBAL CARE targets the international health market on emerging imaging
technologies, innovative diagnostic tools and therapeutic advances.
GLOBAL CARE offers behind a joint counter enlarged opportunities to our industrial and research
partners worldwide. Bringing greater visibility to our R&D offers, GLOBAL CARE aims at mobilizing
multi-disciplinary expertises in response to enterprise needs.
More detailed informations on the GLOBAL CARE consortium members below:
Pasteur MI (Maladies Infectieuses)
The Pasteur Maladies Infectieuses (Pasteur Infectious Diseases) Carnot institute includes five
specialized departments of the Institut Pasteur (Virology, Microbiology, Parasitology & Mycology,
Infection & Epidemiology, Cell Biology & Infection) that, together with four technological platforms,
are dedicated to research on infectious diseases. It brings together basic and applied research
activities involving numerous research partnerships with SMEs and large pharmaceutical and
diagnostic companies.
The goal of research performed at the Pasteur MI Carnot institute is to understand basic
mechanisms of host cells / pathogen interaction, to develop tools to diagnose known or emerging
pathologies, and to perform the clinical validation of vaccines and therapeutic treatments. These
works aim at providing an answer to todays society expectations in public health problems, whether
in developed countries (in particular AIDS, antibiotic resistance) or in developing countries (diseases
of parasitic origin).
Seeing & Hearing Institute
Built in the heart of Paris, the Seeing and Hearing Carnot Institute is one of the most important
research center in Europe on eye and audition diseases.
Conceived as a place of gathering and exchanges, it brings together the three major actors of the
fight against visual and auditive impairments: researchers, clinicians and industrial partners. This
proximity enables the sharing of ideas, skills and platforms, the emergence of new questions and
facilitates the delicate process of translating fundamental discoveries into new treatments.
Our research and development activities are focused onto retinal neuroprotection, sensory
readaptation, innovation in clinical investigation (imaging, diagnosis, surgery) and new solutions for
the visually impaired people (smart-home, smart-city, accessible services).
The Institutes goal is to discover, test and develop treatments and technological innovations of
tomorrow in order to prevent or limit visual and auditive impairment and to improve the autonomy
and the quality of life of patients.
ICM is a private, not-for-profit, Translational Neuroscience Institute based in Paris, France an
rooted in Pitie-Salpetriere, the largest French Neurology Hospital. ICM aggregates more than 500
researchers, a clinical research facility, numerous technological platforms and a start-up incubator
within the same building. Main research fields include Parkinsons disease, Alzheimer, Huntington,
ALS, epilepsy, Multiple Sclerosis and Neurooncology, with a total of +50 clinical trials ongoing. It is
also the national reference center for 13 rare neurological diseases.
THE CURIE INSTITUTE is a leading comprehensive Cancer Center in Paris, France, founded by Marie
Curie in 1909. Our Technology Transfer&Licensing Department is looking for industrial partners
to develop patended innovation (120 families), to enter into preclinical R&D collaboration (drug
discovery) as well as into early-stage clinical collaborations.
GENOPOLE
SECTOR: Other: (developpement agency, association, institution, cluster)
THERAPEuTIC AREA: Cardiovasculr Diseases of the blood, immune
disorders Disease of ear or eye
MEMBER OF COMPETITIVE CLuSTER: Medicen
CONTACTS:
Patricia RIGOU
patricia.rigou@genopole.fr
5, rue Henri Desbrures

Genopole Campus 1
91030 Evry Cedex
Tel: +33 (0)1 60 87 83 00
genopole.fr
Frdric ZAMPATTI
frederic.zampatti@genopole.fr
GENOPOLE is the leading French Science Park dedicated to life sciences.

Located in the Paris Region Biocluster, 30 km south of the city, we offer business support and
incubation to biotech companies in biopharmaceuticals, diagnostics, medical devices, scientific
instrumentation, agrifood, environment and chemistry. We also assist French and foreign companies
in establishing their R&D, commercial or industrial operations in the southern Paris Biocluster to
benefit from world-class hospitals, higher University education, biotech and pharma companies.
71 companies
21 academic research labs
2 148 staff
Biotechs companies

Nombre demploys: 43

Nombre demploys: 43
AFFILOGIC
SECTOR: Therapeutics Diagnostic
THERAPEuTIC AREA: Digestive system Disease of ear or eye
Disease of nervous system
CONTACT:
Nadge PREL
Business Development Manager
nadege@affilogic.com
2, rue de la Houssinire
44000 NANTES
Tel: +33 (0)2 51 12 56 95
www.aflogic.com
AFFILOGIC is a biotech company developing a new class of affinity ligands, Nanofitins, which are
able to selectively bind many targets and have proven excellent tools for:
Targeting (immunolocalization, in vivo neutralization): Therapeutic applications
Capture (affinity chromatography, protein removal): Bioprocessing applications
Detection (immunoassays, Western Blot): Diagnostic applications.
ALIZE PHARMA
SECTOR: Therapeutics
THERAPEuTIC AREA: Endocrine&metabolic diseases Cancer, Oncology
CONTACT:
Valrie WESLEY
vwesley@alz-pharma.com
15, chemin du Saquin

Espace europeen - BAT G
69130 ECULLY
Tel: +33 (0)4 72 18 94 28
www.alz-pharma.com
ALIZ PHARMA is a group of companies specialized in the development of innovative

biopharmaceutical drugs for the treatment of metabolic diseases and rare diseases. ALIZ PHARMA
SAS is dedicated to AZP-531, a peptide derived from unacylated ghrelin, currently in Phase I, to be
developed in type 2 diabetes, the Prader Willi syndrome and some ischemia-related cardiovascular
conditions. ALIZ PHARMA II SAS, is focused on ASPAREC, a new PEGylated recombinant
L-asparaginase for the treatment of acute lymphoblastic leukemia, currently undergoing Phase I
clinical development.
10
ALSACE INTERNATIONAL
Le Sebastopol
3, Quai Klber
67000 STRASBOURG
Tel: +33 (0)3 88 24 77 68
www.alsace.com
International Ofce
ALSACE INTERNATIONAL
40 Wellesley Street
Weston, MA 02493 USA
Tel: +1 (781) 894 7486
Mob. +1 (617) 306 1541
CONTACTS:
Patricia HATESUER
Business Development Manager
p.hatesuer@alsace-international.eu
Andrew CLUTZ
Director, Business Development
ALSACE INTERNATIONAL is the economic development agency of the Alsace region and an active
member of the Alsace BioValley Cluster, a unique environment, rich in business and research
opportunities. Alsace International provides free and confidential customized services to companies
interested in exploring Alsace as a possible location in Europe to carry out activities including R&D,
Service providing, Sales and Marketing, Manufacturing, Regional Headquarters, Clinical trials,
collaborative research (public or private collaborations)
Nombre demploys: 25
AMYLGEN
SECTOR: R&D services/biotechnologies
THERAPEuTIC AREA: Disease of nervous system
CONTACT:
Vanessa VILLARD
vanessa.villard@amylgen.com
Place Eugene Bataillon CC105

34095 MONTPELLIER
Tel: +33 (0)4 67 14 36 86
www.amylgen.com
AMYLGEN has developed a unique and proprietary know-how on Alzheimers disease rodent models
based on central injection of amyloid peptide fragments with validated predictive value. Other
models for schizophrenia, dpression, stroke are also available. AMYLGENs models and techniques
allow fast-scale screening and pre-clinical validation for the pharmaceutical development of new
drug candidates at a very early stage of development.
Date of creation: 1/10/2009

Nombre demploys: 6
11
ARIANA PHARMACEuTICALS
SECTOR: Therapeutics Diagnostic
THERAPEuTIC AREA: Cardiovasculr Digestive system
Diseases of the blood, immune disorders
28, rue du Docteur Finlay
75015 PARIS
Tel: +33 (0)1 44 37 17 00
www.arianapharma.com
International Ofce
Ariana Data Intelligence
Inc. One Broadway - 14th Floor
Cambridge, MA 02142 - USA
CONTACT:
Mohammad AFSHAR
Chairman & CEO
info@arianapharma.com
ARIANA accurately identifies the best patient responder sub-groups in clinical trials, and optimizes
biomarker/diagnostic signatures using its unique technology. ARIANA applies its proprietary
rules-based data analytical approach KEM - to clinical datasets to identify complex relations
that all other approaches miss, thus enabling decision-makers to optimize all possible endpoints
simultaneously. ARIANAs world-class team of experienced, inter-disciplinary scientists includes
PhD biologists, computer scientists, biostatisticians, bio-informatics specialists, chemists and
clinical experts. ARIANA was founded in 2003 as a spin-off from the Institut Pasteur, and has offices
in Paris, France and Cambridge, Mass, USA.
ATLANPOLE BIOTHERAPIES
CONTACT:
Gregory BAUER
bauer@atlanpole.fr
95, route de Gachet

Chteau de la Chantrerie
44307 NANTES Cedex 3
Tel: +33 (0)2 40 25 27 20
www.atlanpolebiotherapies.fr
ATLANPOLE BIOTHERAPIES gives you access to extended skills, from biodiagnostics to biomedicine
in 3 major areas: immunobiotherapies, radiopharmaceuticals and regenerative medicine. For
pharmaceutical companies looking for high level partners devoted to healthcare and biotech,
ATLANPOLE BIOTHERAPIES is a cluster that draws together a community of innovative companies,
fundamental & clinical research organizations and higher education institutions, all located in
Western France.
12
ATLANTIC BONE SCREEN

THERAPEuTIC AREA: Cancer, oncology
CONTACT:
Elisabeth PORCHER
elisabeth.porcher@atlantic-bone-screen.com
3, rue Aronnax
44821 SAINT HERBLAIN Cedex
Tel: +33 (0)2 40 41 11 25
www.atlantic-bone-screen.com
ATLANTIC BONE SCREEN is a French Preclinical CRO providing biological evaluation services in
the field of bone and joint diseases and in the field of bone tumors. We provide In vitro assays( bone
and joint cells, tumor cells), In vivo assays (Experimental models in mice and rats: osteoporosis,
osteoarthritis, rheumatoid arthritis, osteosarcoma, bone metastases from breast and prostate
cancer), ex vivo analyses (histology, immunohistochemisty, imagery, ELISA assays).
ATLANTIC BONE SCREEN has an affiliated company, ATLANCHIMPHARMA provides custom-made
chemical synthesis services
Date of creation: october 2005

Nombre demploys: 10
BIOALTERNATIVES
THERAPEuTIC AREA: Diseases of the blood, immune disorders
Disease of nervous system Endocrine&metabolic diseases
CONTACT:
Maxance VANDEVYVERE
contact@bioalternatives.com
1bis, rue des Plantes

86160 GENAY
Tel: +33 (0)5 49 36 11 37
www.bioalternatives.com
BIOALTERNATIVES is a private company (Contract Research Organization) specialized in Cellular

and Molecular Pharmacology. BIOALTERNATIVES provides services to support the early stages
of drug discovery and the claim substantiation of healthcare compounds using up-to-date in vitro
solutions.

Nombre demploys: 43
13
BIOMEDICAL TISSuES
SECTOR: Therapeutics R&D services/biotechnologies
THERAPEuTIC AREA: Cardiovasculr Skin&subcutaneous tissue
CONTACT:
Valrie DUMAY
vdumay@biometiss.com
IRT UN
8, quai Moncousu
44000 NANTES
Tel: +33 (0)2 28 08 00 37
www.biometiss.com
BIOMEDICAL TISSUES is a Medtech company dedicated to the development of implantable medical

devices for regenerative medicine.
The company provides his customers with services in the field of implants surface treatment
(ISO13485 certified). Besides, Biomedical Tissues develops medical devices, based on a unique
technology of synthetic polymer microfibers synthesis, for soft tissues regeneration.

Nombre demploys: 4
CARLINA TECHNOLOGIES
THERAPEuTIC AREA: Endocrine&metabolic diseases Cancer, Oncology
CONTACT:
Olivier MEYER
omeyer@carlinatech.com
22, rue Roger Amsler

49100 ANGERS
Tel: +33 (0)2 41 24 92 82
www.carlinatech.com
CARLINA TECHNOLOGIES is a biopharmaceutical company specialized in the development of

micro- and nano-medicines. The company provides R&D formulation development services to the
pharmaceutical, veterinary and biotechnology industries as well as it develops improved versions
of first generation drugs for the treatment of cancer and diabetes using innovative encapsulation
platforms.
Date of creation: 23 juillet 2010
14
CELLVAx SAS
THERAPEuTIC AREA: Diseases of the blood, Immune disorders
Cancer, Oncology
CONTACT:
Ming WEI
ming@cellvax-pharma.com
4, rue Pierre Fontaine

91058 EVRY
Tel: +33 (0)1 43 76 32 65
www.cellvax-pharma.com
CELLVAX is a French SME which provides complete preclinical innovating drug validation studies
both in vitro and in vivo (rodents and non-rodents) allowing to accelerate the drug development
process for unmet needs related with severe human diseases, mainly in cancer field.
Date of creation: Juin 2001
CILOA SAS
CONTACT:
Robert MAMOUN
rmamoun@ciloa.fr
Bat. 24, cc107

Universite Montpellier 2
Place E. Bataillon
34095 MONTPELLIER Cedex 5
Tel: +33 (0)4 67 14 39 97
www.ciloa.fr
CILOA offers custom production of fully native membrane proteins on exosomes, therapeutic mAbs
against membrane proteins and collaboration for vaccine development. Ciloa has a full pipeline for
mAb development with:
1. fully native membrane antigens (GPCRs, Kinase receptors, Ion channels, Viral Envelope proteins, etc.).
2. Hybridoma dev. with proprietary powerful immunization protocol.
3. Proprietary Human scFv Phage library focused on membrane Antigens.
4. ELISA screening & SPR characterization.
Date of creation: Mars 2011

Nombre demploys: 8
15
CITOxLAB SAS
CRO - Preclinical services
B.P. 563 - 27005 EVREUX Cedex

Tel: +33 (0)2 32 29 26 26
www.citoxlab.com
CONTACT:
Stphane DE FORTESCU
stephane.defortescu@fr.citoxlab.com
CiToxLAB North America

445, Armand-Frappier Blvd
Laval, Quebec H7V 4B3 - CANADA
CiToxLAB Hungary
Veszprm, Szabadsgpuszta
8200, HUNGARY
CiToxLAB Scantox
Hestehavevej 36A, Ejby
DK-4623 Lille Skensved
DENMARK
CITOXLAB, a leading non-clinical CRO (France, Canada, Denmark and Hungary) offers in vitro and
in vivo safety studies. With more than 40 years of experience in safety and general pharmacology,
genotoxicology, genomics, DART, immunotoxicology, pathology, dermal, ocular, inhalation, infusion,
and carcinogenicity testing, along with ADME and bioanalysis. Our facilities are GLP and AAALAC
certified.

Nombre demploys: 850
CYTuNE PHARMA
THERAPEuTIC AREA: Cancer, Oncology
CONTACTS:
Didier COQUOZ
PharmD, PhD, CDO/C BD&L
didier.coquoz@cytune-pharma.com
7, avenue Amde Mnard

44300 NANTES
Mob.: +33 (0)6 66 49 55 94
www.cytunepharma.com
David Bechard, PhD, MBA, President, COO

david.bechard@cytune-pharma.com
CYTUNE develops CYP0150 that uniquely mimics the major MoA of IL-15 even in pathologic conditions.
CYP0150 restores a potent but balanced immune response and is a unique opportunity within the
successful family of anti-immunosuppressive agents such anti-CTLA4 and anti-PD1. CPY0150 alone
and in combination was shown to have promizing efficacy in different animal tumor models and
to be superior to IL-2. Moreover, CYTUNE develops a broad portfolio of potent immunocytokines,
i.e. monoclonal antibody fused to CYP0150. These ICKs enable to manage the product Life Cycle
Management for existing blockbusters and to increase the efficacy of existing or future antibodies.
16
DRuGABILIS
CONTACT:
Joel VACUS
joel.vacus@drugabilis.com
5, rue Jean Baptiste Clment

92290 CHATENAY MALABRY
Tel: +33 (0)1 46 61 28 50
www.drugabilis.com
DRUGABILIS is a CRO specialized in pharmaceutical physicochemical characterization and

formulation as applied to the early selection of new drug candidates and their formulations.
DRUGABILIS management and scientists have an extensive experience of industrial pharmaceutical
research support. The company offer includes solubility and stability screenings, salt and
polymorphism screenings, formulation design for animal dosing (any route of administration/any
animal model/low-soluble compounds...), preformulation studies, phase I formulation strategy
set-up.
EuKARYS
CONTACT:
Benjamin BERTRAND
benjamin@eukarys.com
Ppinire Genopole Entreprises CAMPUS 3 - 4, rue Pierre Fontaine

91058 EVRY Cedex
Mob.: +33 (0)6 24 00 17 53
www.eukarys.com
High performance high yield cell-free messenger RNA production systems for research, cell
therapies, human vaccines, cell reprogramming. The C3P3 mRNA Production System has three
decisive competitive advantages: 1) increased mRNA yields; 2) fully mature mRNA with very high
rate of native capping, and poly(A)tail, enhancing protein expression; 3) Easy-to-Use and Quick:
One-step process instead of 3 or 4 to a produce completely capped, poly(A)-tailed mRNA. Other
advantages: stability, immunogenicity, poly(A)-tails of equal or customized length, non-viral.

Nombre demploys: 3
17
GENBIOTECH
THERAPEuTIC AREA: Diseases of the blood, immune disorders
Skin&subcutaneous tissue
CONTACT:
mail@genbiotech.com
Z.I. les 3 Moulins

280, rue de Goa - B.P. 60053
06901 SOPHIA-ANTIPOLIS
Tel: +33 (0)4 92 91 32 23
www.genbiotech.com
The creation of GENBIOTECH, a spinoff of the Laboratoires Genvrier results of 15 years of strategic
involvement in biotechnological research with one goal: to improve the quality of life of patients in
the field of rheumatology, dermatology and gynecology worldwide.
GENBIOTECH aims to bring together people and resources required for Research and Development
and Marketing innovative biotechnological therapies adapted to patients needs.
GENOPOLE
Biocluster
THERAPEuTIC AREA: Cardiovasculr Diseases of the blood, immune
disorders Disease of ear or eye
CONTACTs:
Patricia RIGOU
patricia.rigou@genopole.fr
5, rue Henri Desbrures

Genopole Campus 1
91030 EVRY Cedex
Tel: +33 (0)1 60 87 83 00
www.genopole.fr
Frdric ZAMPATTI
frederic.zampatti@genopole.fr
GENOPOLE is the leading French Science Park dedicated to life sciences.

Located in the Paris Region Biocluster, 30 km south of the city, we offer business support and
incubation to biotech companies in biopharmaceuticals, diagnostics, medical devices, scientific
instrumentation, agrifood, environment and chemistry. We also assist French and foreign companies
in establishing their R&D, commercial or industrial operations in the southern Paris Biocluster to
benefit from world-class hospitals, higher University education, biotech and pharma companies.
- 71 companies
- 21 academic research labs
- 2 148 staff
18
ICM
Mental & behavioural disorders Cancer, oncology
CONTACT:
Alexis GENIN
Directeur des Applications de la
Recherche
alexis.genin@icm-insitute.org
BRAIN & SPINE INSTITUTE (ICM)

Hpital Piti Salptrire
47, boulevard de lHpital
75013 PARIS
Tel: +33 (0)1 57 27 40 00
http://research.icm-institute.org/
ICM is a private, not-for-profit, Translational Neuroscience Institute based in Paris, France an

rooted in Pitie-Salpetriere, the largest French Neurology Hospital. ICM aggregates more than
500 researchers, a clinical research facility, numerous technological platforms and a start-up
incubator within the same building. Main research fields include Parkinsons disease, Alzheimer,
Huntington, ALS, epilepsy, Multiple Sclerosis and Neurooncology, with a total of +50 clinical trials
ongoing. It is also the national reference center for 13 rare neurological diseases.

ICTA
SECTOR: Therapeutics R&D services/biotechnologies Diagnostic
International Ofce
ICTA GmbH - Lebacher
Strasse 4 - D-66113
Saarbrcken
ICTA INTERNATIONAL CLINICAL TRIALS

ASSOCIATION
11, rue du Bocage
21121 FONTAINE LES DIJON
Tel: +33 (0)3 80 53 40 00
www.icta.fr
CONTACT:
Olivier HUMBEY
olivier.humbey@icta.fr
ICTA (INTERNATIONAL CLINICAL TRIALS ASSOCIATION) is an international privately-owned CRO

with 30 years of experience in clinical R&D, pharmaco-epidemiology and expanded access programs
for APIs, cell therapies, diagnostics and medical devices. ICTAs international operations in Europe
and the USA provide full clinical research or a la carte services in traditional and adaptive clinical
trials from Early Phase to Late Phase across a broad range of therapeutic areas...

19
IN-CELL-ART
SECTOR: Therapeutics Diagnostic R&D services/biotechnologies
THERAPEuTIC AREA: Infectious and parasistic diseases Cancer, oncology
CONTACT:
Sohei FUKUYAMA
MBA Business Development & Alliance
Management
sohei.fukuyama@incellart.com
21, rue de la Noue Bras de Fer

44200 NANTES
Tel: +33 (0)2 40 71 67 17
www.incellart.com
ICA was founded in 2005 by a research team including a Nobel Prize laureate. ICA is specialized
in nanocarriers for macromolecule delivery and it has collaborations with DARPA (US Ministry of
Defense), Sanofi Pastuer, Merial and more. In 2012, Deloitte awarded ICA as one of the fastest
growing biopharmaceutical firms between 07 and 11 in France. Currently, ICA has 4 core activities
based on the delivery system: Vaccine, Gene Therapy , Antibody Discovery and iPSc,
IRIS PHARMA
THERAPEuTIC AREA: Disease of ear or eye
CONTACT:
Pierre-Paul ELENA
info@iris-pharma.com
Alle Hector Pintus

06610 LA GAUDE
Tel: +33 (0)4 93 59 49 59
www.iris-pharma.com
A leading contract research organization (CRO) dedicated to ophthalmology, IRIS PHARMA helps
clients around the world navigate every stage of the drug and device development process
including in vivo screening, proof of concept, ocular efficacy, GLP preclinical studies, bioanalysis,
clinical trials, and marketing surveys. IRIS PHARMA has partnered with clients to bring more than
40 ocular drugs and medical devices to market in the past 24 years, in addition to offering consulting
services to help clients determine the best indication for molecules and products in development.
This CRO has expertise in all ophthalmic indications, and supports clients ranging from small startups to large pharmaceutical companies in moving forward products that directly or indirectly affect
eye health.
Nombre demploys: 60
20
KEOSYS SAS
SECTOR: Diagnostic R&D services/biotechnologies
Other: (developpement agency, association, institution, cluster)
Medical Imaging Services for clinical Trials
1, Impasse Augustin Fresnel
44815 SAINT-HERBLAIN
Tel: +33 (0)2 40 92 26 13
www.keosys.com
International Ofce
Philadelphie (U.S.A)
CONTACT:
Lydia BEHLOUL
lbe@keosys.com
KEOSYS Medical Imaging is a global company specialized in IT applied to Medical Imaging within
clinical research and medical diagnosis. KEOSYS offers full medical imaging services for phase
II-III-IV drug and device medical imaging clinical trials whatever the imaging modalities and
the therapeutic areas. KEOSYS expertise relies on its deep knowledge of the medical imaging
requirements in clinical study projects and on its expert medical team (radiologists, nuclear medicine
physicians, gastroenterologists, cardiologists, neurologists, rheumatologists, dermatologists).
L2D SERVICES SARL

CONTACT:
J. KEARSEY
jkearsey@leadstodevelopment.com
leads to development
166, boulevard du Montparnasse
75014 PARIS
www.leadstodevelopment.com
LEADS TO DEVELOPMENT (L2D) specializes in the early-stage development of therapeutic

products. We offer consultancy, regulatory and operational management services to our clients in
order to help them bridge the gap between therapeutic lead identification and clinical development.
Our clients benefit from our development expertise without having to build additional internal
headcount, whilst we ensure that their products are advanced rapidly and cost effectively to clinical
proof of concept. We offer a personal service carefully tailored to our customers needs that
maintains the transparency, flexibility and availability associated with an internal team

Nombre demploys: 5
21
MEDINCELL
THERAPEuTIC AREA: cCardiovasculr Digestive system
Parc Clment Ader

1, avenue Charles Cros
34830 JACOU
Tel: +33 (0)4 67 41 99 74
www.medincell.com
International Ofce
MedinCell Corporation
10451 Roselle St, Suite 200
San Diego CA 92121
CONTACT:
Sebastien ENAULT
sebastien.enault@medincell.eu
MEDINCELLs controlled-release delivery platform offers wide-ranging durationsfrom several

days up to one yearfor many small molecules and biologics, and requires no API modification.
Current commercial partnerships aim to address delivery hurdles across arthritis, oncology,
contraception, diabetes, and our low-cost manufacturing enables partners to target fast-growing
emerging markets.
METABOLYS SAS
Endocrine&metabolic diseases Cancer, oncology
CONTACT:
Gabriel BAVEREL
baverel@metabolys.com
Laennec Faculty of Medicine

7-11, rue G. Paradin
69008 LYON
Mob.: +33 (0)6 84 85 57 75
www.metabolys.com
METABOLYS has a drug discovery line in the diabetes field. Six antidiabetic candidates are protected
by 4 patents; one of them is being developed and will be out-licensed.
METABOLYS has also a service activity consisting of predicting the safety and efficacy of drug
candidates using a metabolic flux analysis approach.

Nombre demploys: 6
22
METABRAIN RESEARCH
SECTOR: Therapeutics Diagnostic R&D services/biotechnologies
THERAPEuTIC AREA: Cardiovasculr Disease of nervous system
Endocrine&metabolic diseases
CONTACT:
Valerie AUTIER
v.autier@metabrainresearch.com
4, avenue du pdt f. Mitterrand

91380 CHILLY MAZARIN
Tel: +33 (0)1 69 19 41 50
www.metabrainresearch.com
METABRAIN is a diabetes research center (Paris area). Its 30 collaborators operate integrated
and disease oriented medicinal chemistry, molecular, cellular and animal pharmacology, gather
long term industrial experience in discovery and drug development. Since 2009, METABRAIN is
conducting research partnerships with main French Biotechs and Pharmas. It develops drugs and
nutraceuticals and associated biomarkers that address several interconnected chronic diseases
such as diabetes, obesity, muscle dysfunction and memory troubles, for the elder population which
requires alternatives to existing therapies.

Nombre demploys: 30
MYELOMAx
THERAPEuTIC AREA: Cancer, oncology
CONTACT:
contact@myelomax.com
IRS_UN
8, quai Moncousu
44007 NANTES
Tel: +33 (0)2 28 08 00 40
www.myelomax.com
MYELOMAX is a french CRO specialized in preclinical evaluation services in the field of multiple
myeloma. Our mission is to assist our clients in the evaluation of drug efficacy, mechanism of action,
combination with approved drugs, identification of biomarkers using our large and unique collection
of Human Multiple Myeloma Cell Lines covering the molecular and functional diversity of Multiple
Myeloma.
23
OTR3
THERAPEuTIC AREA: Cancer,oncology Skin&subcutaneous tissue
CONTACT:
Denis BARRITAULT
denis.barritault@otr3.com
4, rue Franaise
75001 PARIS
Tel: +33 (0)1 83 62 78 83
www.otr3.com
OTR3 is developing products in regenerative medicine from innovative proprietary molecules: the
RGTA. RGTA are biodegradable polysaccharides engineered to restore the cellular microenvironment
after lesion and favor tissue regeneration without external input of stem cells. Two products are on
the market: CACIPLIQ20 and CACICOL20 to treat skin and corneal ulcers. Two developments are in
clinical trials to treat mucositis and radiation dermatitis in cancer patients. Marketing authorization
is expected within 1 year. OTR3 is looking for licensees and developments partners.
Date of creation: July 2000

Nombre demploys: 13
OxELTIS
THERAPEuTIC AREA: Infectious and parasistic diseases Cancer, oncology
CONTACT:
Jean-Marc ALLAIRE
contact@oxeltis.com
Cap Gamma
1682, rue de la Valsire
C.S. 27384
34189 MONTPELLIER Cedex 4
Tel: +33 (0)4 99 23 50 36
www.oxeltis.com
OXELTIS is a medicinal chemistry service company delivering integrated solutions for managing and
executing medicinal and fine organic chemistry projects in the field of NCE discovery and optimization.
OXELTIS is particularly active in the anti-infective and oncology fields. OXELTIS team expertise and
background is related to medchem research for the past 10 years. Its expertise in organic chemistry
is in heterocycles, macrocycles, sugars, nucleos(t)ides and phosphorus chemistry. OXELTIs is
located in Montpellier-France and was founded in 2010 by former management and research team
from Idenix Pharmaceuticals
Date of creation: September 2010
24
PELVIPHARM SAS
CONTACT:
Delphine BEHR-ROUSSEL
d.behr.roussel@pelvipharm.com
Orsay Parc
86, rue de Paris
91400 ORSAY
Tel: +33 (0)1 70 42 93 39
www.pelvipharm.com
PELVIPHARM is a CRO delivering preclinical research services across a range of therapeutic

areas including urology (BPH, OAB, NDO, SCI, SUI, IC), sexual (ED, PE, FSD) and cardiovascular
medicine (Hypertension, Atherosclerosis, Metabolic Syndrome, Diabetes,Myocardial Infarction).
PELVIPHARM provides customized outsourcing services to clients according to their outsourcing
needs, using both in vivo experimental models and in vitro animal and human tissue-based specific
research services based on the most recent exploration methods.

Nombre demploys: 14 FTE
PORSOLT SAS
Disease of ear or eye
CONTACT:
Sbastien BRECHE
sbreche@porsolt.com
Z.A. de Glatign
53940 LE GENEST SAINT ISLE
Tel: +33 (0)2 43 69 36 07
www.porsolt.com
PORSOLT is a long-established preclinical CRO with an international reputation for expertise in

physiopathological models, customized procedures and tailored solutions for discovering treatments
of psychiatric & neurological diseases, acute & chronic pain, inflammation, cardio vascular diseases,
and metabolic disorders. PORSOLT also offers services for safety evaluation of drug candidates from
screening to pre-Phase 1 regulatory studies (ICH S7), in full GLP compliance. PORSOLTs safety
program includes full assessment of arrhythmogenic risk and abuse/dependence liability.
25
POxEL SA
THERAPEuTIC AREA: Endocrine&metabolic diseases
CONTACT:
Pascale MALGOUYRES
pascale.malgouyres@poxelphama.com
200, avenue Jean Jaurs

69007 LYON
Tel: +33 (0)4 37 37 20 10
www.poxel.com
POXEL is a biopharmaceutical company developing innovative first-in-class drugs with a primary

focus on Type 2 diabetes. The company develops novel treatments before partnering with
pharmaceutical companies. POXEL operates independently as a lean organization with strong
in-house drug development and business expertise. Its R&D pipeline consists in innovative
programs with new mechanism of action, agents profiled for their activity on glucose metabolism
and cardiovascular risk factors, all with an improved safety profile compared to current available
therapies.

Nombre demploys: 13
PRESTwICK CHEMICAL SAS

CONTACT:
Paul BIKARD
paul.bikard@prestwickchemical.fr
220, boulevard Gonthier dAndernach

STRASBOURG-ILLKIRCH
Tel: +33 (0)3 69 20 16 00
www.prestwickchemical.com
PRESTWICK CHEMICAL is a drug discovery company that successfully identifies hits for the projects
target and optimizes the hits into clinical candidates. With our premium partners, we have developed
the capacity to integrate the whole drug research: Hit identification using smart screening libraries
and/or large scale pharmacophore based virtual screening, hit validation, hit to lead expansion, lead
optimization and profiling and have unprecedented success towards development.
26
PuP PHARMA SAS

THERAPEuTIC AREA: Digestive system Disease of nervous system
Injury, poisoning
CONTACT:
David CHAUVIER
dchauvier@puppharma.fr
102, avenue Gaston Roussel

93230 Romainville
Tel: +33 (0)9 81 30 80 12
www.puppharma.fr
PUP PHARMAs unique experimental services tailored to our customers specific perinatal and
paediatric applications, allowed preclinical efficacy and safety drug evaluation in the context of
pathological/physiological conditions from prematurity to childhood. Our pharmacological services
allow either complying with the mandatory Pediatric Investigation Plan or identifying new indications
for yours products in the field of Central Nervous System, Pulmonary or Inflammatory Systems.
Date of creation: aout 2010
PxTHERAPEuTICS
CONTACT:
Claire UNTEREINER
claireuntereiner@px-therapeutics.com
Minatec BHT52A
7, parvis Louis Nel
38040 GRENOBLE
Tel: +33 (0)4 38 02 36 50
www.px-therapeutics.com
PXTHERAPEUTICS, located in Grenoble (France), provides services in the field of recombinant

protein development and GMP manufacturing. PXTHERAPEUTICS proposes custom programs
targeting the development of monoclonal antibodies, humanization of therapeutic antibodies,
protein engineering and optimization, feasibility studies, process development up to clinical and
small-scale commercial batch production, in bacteria, yeasts or mammalian cells. Our subsidiary
Promise Advanced Proteomics provides products and services in the field of quantitative proteomics.
27
QuINTEN
CONTACT:
Alexandre TEMPLIER
a.templier@quinten-france.com
11, rue Galvani

75017 PARIS
Tel: +33(0)1 45 74 33 05
www.quinten.com
QUINTEN is a strategy and operations consulting firm specialized in leveraging biomedical data for
pharmaceutical, biotechnology and cosmetics companies.
QUINTENs knowhow complements traditional modeling and data-mining techniques, since it
enables to identify, characterize and enhance the value of sub-groups corresponding to best and
worst practice in terms of patients response or resistance to a treatment, and occurrence of
undesirable side-effects.

Nombre demploys: 15
SKuLDTECH
SECTOR: Diagnostic R&D services/biotechnologies
Infectious and parasistic diseases Cancer, oncology
CONTACT:
Didier RITTER
info@skuldtech.com
1682, rue de la Valsire

C.S. 77394
34184 MONTPELLIER
Tel: +33 (0)4 67 41 97 48
www.skuldtech.com
SKULDTECH aims to discover and validate new genomic and pharmacogenomic biomarkers for
diagnostics and therapeutic purposes. Its approach is based on Digital Gene Expression method,
New Generation Sequencing (NGS) technologies associated with its proprietary bionformatics and
biostatistics tools. This expertise enables the Company to provide genomic, pharmacogenomic
and transcriptomic services, as well as innovative diagnostics associated with new therapeutics
especially in cancer, rare diseases and infectious diseases.
28
SYNCROSOME
CONTACT:
Arnaud PEYRONNIER
dvpt@syncrosome.com
Case Postale 908

Luminy biotech entreprises
163, avenue de Luminy
13288 MARSEILLE
Tel: +33 (0)4 95 05 31 80
www.syncrosome.com
SYNCROSOME is focused on In Vivo Efficacy Studies dedicated to Discovery and Preclinical stage
with more than 25 Animal Models, to provide you the right data to make the right decision. We offer
our services and our expertise in the development of drugs in: GASTROENTEROLOGY, CENTRAL
NERVOUS SYSTEM, CARDIOVASCULAR, RESPIRATORY, INFLAMMATION. We perform also
Pharmacokinetics studies (multi-species). Concerning PK studies, we pay a special attention to
CNS-PK to evaluate the in vivo BBB passage of your compounds.

Nombre demploys: 14
TExCELL
CONTACT:
Bernard PLICHON
info@texcell.com
Bt. Genavenir 5
1, rue Pierre Fontaine
91058 EVRY Cedex
Tel: +33 (0)1 60 91 33 10
www.texcell.com
TEXCELL is a world-renowned company that provides Biosafety and immunology services in full
compliance with GLP and GMP standards.Thanks to our in-depth experience of providing viral safety
testing and virus validation studies, we have provided support to a large number products licensed
by the FDA, the EMA and the MHW. TEXCELL is also your central lab for pre-clinical and clinical
trials. We offer a dedicated technology platform in immunology. Based in France near Paris (Evry),
TEXCELL has also a subsidiary in USA, with facilities in Middletown, MD., and soon in Frederick,
specialized in no GMP Cell culture and GLP compliant viral clearance testing services.
29
TROPHOS
THERAPEuTIC AREA: Cardiovasculr Disease of nervous system
CONTACT:
Julien VEYS
info@trophos.com
Parc scientifique de Luminy

Case 931
13288 MARSEILLE
Tel: +33 (0)4 91 82 82 82
www.trophos.com
TROPHOS is a late stage pharmaceutical company whose strategy is to create and realise value from
its proprietary, innovative, cholesterol-oximes compound family of mitochondrial pore modulators
by taking at least one program to clinical validation for orphan/niche indications in neurology
and acute cardiology before an exit for investors. The Company has its lead product, olesoxime
(TRO19622), in phase 2/3 development and TRO40303 in phase 2 development with funding secured
up to the next step of value creation.
VFP THERAPIES
VFP Therapies
Drugs: Highway to the Brain
C : 100 - m : 47 - j : 0 -n : 40

Mmental & behavioural disorders Cancer, oncology
Typographie
Century regular
c : 100 -m : 10 -j : 0 -n : 10
CONTACT:
Francis MARSAIS
President and CEO
contact@vfp-therapies.com
15, rue Franois Couperin

76000 ROUEN
Mob.: +33 (0)6 80 32 57 64
www.vfp-therapies.com
VFP THERAPIES is a young French company who has devised an innovative therapeutic approach
aimed at treating brain diseases such as Alzheimers Disease by means of highly selective
bioprecursor drugs. Such prodrugs do not deploy activity before they crossed the blood-brainbarrier, and hence do not induce significant side effects. Besides, one so can target receptor sites
in the brain in a more selective way. The required amount of active principle as well as its toxicity
can thereby be decreased. The core business of VFP THERAPIES is the development of proprietary
drugs at the same time as joined development work on behalf of pharmaceutical and biotechnology
companies.
Date of creation: aot 2012

Nombre demploys: 6
30
notes
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
31
notes
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
32
notes
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
..................................................................................................................................................................
33
BIO EUROPE 2O13

CONVENTION
The French participation is organized by UBIFRANCE
HEAD OFFICE IN PARIS

77, boulevard Saint-Jacques
75014 PARIS - FRANCE
Tel: +33 (0)1 40 73 33 88
Fax: +33 (0)1 40 73 30 39
Jennifer OLSZOWY
jennifer.olszowy@ubifrance.fr
CONTACT IN AUSTRIA
uBIFRANCE Vienna
Reisnerstrasse 50/10
1030 VIENNE - AuTRICHE
Tel: +43 (0)1 712 63 57 64
Mascha PAULIN
mascha.paulin@ubifrance.fr
WEBSITE
www.ubifrance.com

French Biotech and Pharma Companies 17-10-2013!17!20

Загружено:

Сведения о документе

Авторское право

Доступные форматы

Поделиться этим документом

Поделиться или встроить документ

Параметры публикации

Этот документ был вам полезен?

Это неприемлемый материал?

Авторское право:

Доступные форматы

French Biotech and Pharma Companies 17-10-2013!17!20

Загружено:

Авторское право:

Доступные форматы

FRENCH BIOTECH

BIO EUROPE 2O13

95, route de Gachet

Date of creation: 2005

MEDICEN PARIS REGION

3-5, impasse Reille

The Global Partnership Research Initiative

of the Carnot Human Health Institutes

5, rue Henri Desbrures

GENOPOLE is the leading French Science Park dedicated to life sciences.

Date of creation: 1996

Date of creation: 1996

Date of creation: 2010

15, chemin du Saquin

ALIZ PHARMA is a group of companies specialized in the development of innovative

Place Eugene Bataillon CC105

Date of creation: 1/10/2009

Date of creation: 2003

95, route de Gachet

Date of creation: 2005

ATLANTIC BONE SCREEN

Date of creation: october 2005

1bis, rue des Plantes

BIOALTERNATIVES is a private company (Contract Research Organization) specialized in Cellular

Date of creation: 1996

BIOMEDICAL TISSUES is a Medtech company dedicated to the development of implantable medical

Date of creation: 01/10/2010

22, rue Roger Amsler

CARLINA TECHNOLOGIES is a biopharmaceutical company specialized in the development of

Date of creation: 23 juillet 2010

4, rue Pierre Fontaine

Date of creation: Juin 2001

Bat. 24, cc107

Date of creation: Mars 2011

B.P. 563 - 27005 EVREUX Cedex

CiToxLAB North America

Date of creation: 1969

7, avenue Amde Mnard

David Bechard, PhD, MBA, President, COO

Date of creation: 2007

5, rue Jean Baptiste Clment

DRUGABILIS is a CRO specialized in pharmaceutical physicochemical characterization and

Date of creation: 2004

Ppinire Genopole Entreprises CAMPUS 3 - 4, rue Pierre Fontaine

Date of creation: 210

Z.I. les 3 Moulins

Date of creation: 24/10/2012

5, rue Henri Desbrures

GENOPOLE is the leading French Science Park dedicated to life sciences.

BRAIN & SPINE INSTITUTE (ICM)

ICM is a private, not-for-profit, Translational Neuroscience Institute based in Paris, France an

Date of creation: 2010

ICTA INTERNATIONAL CLINICAL TRIALS

ICTA (INTERNATIONAL CLINICAL TRIALS ASSOCIATION) is an international privately-owned CRO

Date of creation: 01/05/1984

21, rue de la Noue Bras de Fer

Date of creation: 2005

Alle Hector Pintus

Date of creation: 2001

L2D SERVICES SARL

LEADS TO DEVELOPMENT (L2D) specializes in the early-stage development of therapeutic

Date of creation: 2009

Parc Clment Ader

MEDINCELLs controlled-release delivery platform offers wide-ranging durationsfrom several